ESC 2021: Late-breaking Science Video Collection
Published: 02 September 2021
-
Views:
6256 -
Likes:
7
-
Views:
6256 -
Likes:
7
-
25m 18sPart 1 | Session 1 View from the Thoraxcenter – What's Hot at ESC 2021 Nicolas M Van Mieghem, Joost Daemen
-
36m 1sPart 1 | Session 2 View from the Thoraxcenter: ESC 21 Late-breaking Science Wrap Up Joost Daemen, Nicolas M Van Mieghem
-
19m 47sPart 2 | Session 1 ESC 2021 Discussion: The EMPEROR-Preserved Trial Harriette Van Spall, Stefan Anker
-
15m 2sPart 2 | Session 2 ESC 2021 Discussion: The FIGARO-DKD Trial Bertram Pitt, Harriette Van Spall
-
20m 8sPart 2 | Session 3 ESC 2021 Discussion: The EMPEROR-Pooled Study Milton Packer, Harriette Van Spall
-
6m 33sPart 3 | Session 1 ENVISAGE-TAVI AF: Edoxaban noninferior to warfarin for adverse events after TAVI George D Dangas
-
4m 39sPart 3 | Session 2 SYNTAX II Trial: 5yr Data Shows Reduction in MACE in PCI Adrian P Banning
-
8m 40sPart 3 | Session 3 TWILIGHT-HBR: Ticagrelor Monotherapy in HBR Patients Undergoing PCI Davide Cao
-
5m 21sPart 3 | Session 4 The LAAOS III Study: Surgical AFIB Ablation Evaluation Richard Whitlock
-
9mPart 3 | Session 5 TWILIGHT-Stent: Ticagrelor Monotherapy According to Stent Type George D Dangas
-
5m 43sPart 3 | Session 6 STOPDAPT-2 ACT: 1-Month DAPT Followed by Clopidogrel Monotherapy in ACS Hirotoshi Watanabe
-
5m 41sPart 3 | Session 7 SPLENDOR: Metabolic Surgery and Risk of MACE in NASH Ali Aminian
-
5m 11sPart 3 | Session 8 RESPONSE-2: Benefits of Community-based Lifestyle Programme Were Lost After 1yr in CAD Patients Harald Thune Jorstad
-
6m 9sPart 3 | Session 9 VOYAGER PAD: Rivaroxaban in Symptomatic PAD With & Without Comorbid Diabetes Cecilia Low Wang
-
5m 50sPart 3 | Session 10 Micra CED: 2-Year Outcomes with Leadless Pacing Jonathan Piccini
-
10m 53sPart 3 | Session 11 RIPCORD 2: FFR During Angiography Did Not Improve Patient Outcomes Nick Curzen
Overview
Our regular review series View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provide a concise analysis of the late-breaking science results and spotlight impactful data.
For a deeper dive into key clinical trial data, Dr Harriette Van Spall (McMaster University, Hamilton, CA) interviewed principal investigators on their studies, learnings, and applicability to clinical practice in her regular Late-Breaker Discussion Series.
Short, accessible Expert Interviews were conducted with select faculty focusing on the results, applicability, and impact on future research.
More from this programme
Part 1
View from the Thoraxcenter
Part 2
Late-breaker Discussion Series
Part 3
Expert Interviews
Part 4
Masterclass with Dr Harriette Van Spall & Dr Birgit Vogel
Faculty Biographies
Harriette Van Spall
Associate Professor of Medicine, Director of E-Health and Virtual Care
Dr Harriette Van Spall is an Associate Professor of Medicine and cardiologist and serves as Director of E-Health at McMaster University, Canada. She completed her medical and postgraduate clinical training at the University of Toronto and earned a Master of Public Health degree at Harvard University, US. Dr Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on heart failure, health services, and health disparities.
She has garnered more than $4 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high-impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.
Dr Van Spall is an Editorial Board…